Viking Therapeutics (VKTX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
H.C. Wainwright Assumes Viking Therapeutic (VKTX) at Buy, 'An Underappreciated Microcap'
November 10, 2017 7:17 AM ESTH.C. Wainwright assumes coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $7.00.
Analyst Ed Acre takes over coverage of the name and comments "We view Viking as an underappreciated microcap stock with five novel drugs in the... More
